Corbus Pharmaceuticals Holdings, Inc. Operating Lease, Expense
Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported Operating Lease, Expense of $1.70 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2024-03-12
- Corbus Pharmaceuticals Holdings, Inc. operating lease, expense for the quarter ending 2020-12-31 was $310.12K, a 46.72% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, expense for the quarter ending 2020-09-30 was $310.12K, a 0.96% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, expense for the quarter ending 2020-06-30 was $310.12K, a 0.96% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, expense for the quarter ending 2020-03-31 was $310.12K, a 54.93% increase year-over-year.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, expense for fiscal 2023 was $1.70M, a 2.87% increase from fiscal 2022.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, expense for fiscal 2022 was $1.65M, a 39.42% increase from fiscal 2021.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, expense for fiscal 2021 was $1.19M, a 4.44% decline from fiscal 2020.
- Corbus Pharmaceuticals Holdings, Inc. operating lease, expense for fiscal 2020 was $1.24M, a 20.92% increase from fiscal 2019.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 3 month as first filed | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|---|
| 2023-12-31 | $1.70M 10-K · filed 2024-03-12 | ||||
| 2022-12-31 | $1.65M 10-K · filed 2024-03-12 | ||||
| 2021-12-31 | $1.19M 10-K · filed 2023-03-07 | ||||
| 2020-12-31 | $310.12K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $620.24K derived: sum of 2 quarters · filed 2022-03-08 | $930.36K derived: sum of 3 quarters · filed 2022-03-08 | $1.24M 10-K · filed 2022-03-08 | |
| 2020-09-30 | $310.12K 10-Q · filed 2020-11-09 | $620.24K derived: sum of 2 quarters · filed 2020-11-09 | $930.35K 10-Q · filed 2020-11-09 | $1.14M derived: sum of 4 quarters · filed 2021-03-15 | |
| 2020-06-30 | $310.12K 10-Q/A · filed 2020-08-31 | $620.24K 10-Q/A · filed 2020-08-31 | $831.61K derived: sum of 3 quarters · filed 2021-03-15 | $1.14M derived: sum of 4 quarters · filed 2021-03-15 | |
| 2020-03-31 | $310.12K 10-Q · filed 2020-05-11 | $521.49K derived: sum of 2 quarters · filed 2021-03-15 | $828.67K derived: sum of 3 quarters · filed 2021-03-15 | $1.14M derived: sum of 4 quarters · filed 2021-03-15 | |
| 2019-12-31 | $211.37K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $518.55K derived: sum of 2 quarters · filed 2021-03-15 | $825.74K derived: sum of 3 quarters · filed 2021-03-15 | $1.03M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $307.18K 10-Q · filed 2020-11-09 | $307.18K 10-Q · filed 2019-11-07 | $614.36K derived: sum of 2 quarters · filed 2020-11-09 | $814.53K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $307.18K 10-Q/A · filed 2020-08-31 | $507.34K 10-Q/A · filed 2020-08-31 | |||
| 2019-03-31 | $200.16K 10-Q · filed 2020-05-11 | ||||
| 2018-09-30 | $146.23K 10-Q · filed 2019-11-07 | $293.98K derived: sum of 2 quarters · filed 2019-11-07 | $440.97K 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $147.75K 10-Q · filed 2019-08-08 | $294.74K 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $146.99K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |